Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 12Lymphoid 11Genitourinary 10Gastrointestinal 10CNS 7Myeloid 6Thoracic 3Plasma cell 3Other hematologic neoplasm 3Head & Neck 3Gynecologic 3Endocrine 3Tumor-Agnostic 2NET 2Dermatologic 1Breast 1

Conditions

Immunoglobulin Light-chain Amyloidosis 2Multiple Myeloma 1

Interventions

Dexamethasone 124daratumumab 73Lenalidomide 72Bortezomib 61pomalidomide 45Cyclophosphamide 41carfilzomib 40Calcium Dobesilate 36Specimen Handling 34Biopsy 30Magnetic Resonance Spectroscopy 27belantamab mafodotin 24isatuximab 20fludarabine 20dexamethasone acetate 18dexamethasone 21-phosphate 18auricularum 18Melphalan 18talquetamab 16iberdomide 16fludarabine phosphate 12selinexor 11elotuzumab 10X-Rays 10tocilizumab 9Nivolumab 8Sirolimus 7Crizotinib 7trametinib 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phantoms, Imaging × Plasma cell × 90 days × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05981209 2026-05-13

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
12 enrolled
Plasma cell

Multiple Myeloma

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Mayo Clinic

Phase 2 Recruiting
96 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡